Table 1 Patient characteristics.
Characteristics | Furmonertinib + Bev(%) (N = 62) | Furmonertinib(%) (N = 42) | P |
|---|---|---|---|
Age in years, median (range) | 57 (31–77) | 57 (34–77) | |
<60, n (%) | 39 (62.9) | 29 (69.0) | 0.52 |
≥60, n (%) | 23 (37.1) | 13 (31.0) | |
Sex, n (%) | |||
Male | 23 (37.1) | 16 (38.1) | 0.92 |
Female | 39 (62.9) | 26 (61.9) | |
Histological type, n (%) | |||
Adenocarcinoma | 62 (100) | 42 (100) | NA |
ECOG PS n (%) | |||
2 | 21 (33.9) | 17 (40.5) | 0.78 |
3 | 22 (35.5) | 13 (30.9) | |
4 | 19 (30.6) | 12 (28.6) | |
Smoking status, n (%) | |||
Smoker | 13 (21.0) | 14 (33.3) | 0.16 |
Nonsmoker | 49 (79.0) | 28 (66.7) | |
EGFR mutation, n (%) | |||
EGFR L858R | 36 (58.1) | 19 (45.3) | 0.43 |
EGFR-19del | 15 (24.2) | 14 (33.3) | |
Other EGFR mutations | 11 (17.7) | 9 (21.4) | |
Concurrent BM, n (%) | |||
Yes | 28 (45.2) | 18 (42.9) | 0.82 |
No | 34 (54.8) | 24 (57.1) | |
Lines of treatment, n (%) | |||
≤3 | 32 (51.6) | 26 (61.9) | 0.30 |
>3 | 30 (48.4) | 16 (38.1) | |
Classification of extracranial lesion after LM, n (%) | |||
SD | 56 (90.3) | 36 (85.7) | 0.47 |
PD | 6 (9.7) | 6 (14.3) | |
Previous third-generation EGFR-TKI therapy, n (%) | |||
Osimertinib | 37 (59.8) | 29 (69.0) | 0.68 |
Almonertinib | 29 (46.8) | 16 (38.1) | |
Furmonertinib | 15 (24.2) | 10 (23.8) | |
Intrathecal chemotherapy, n (%) | |||
Yes | 51 (82.3) | 33 (78.6) | 0.64 |
No | 11 (17.7) | 9 (21.4) | |
WBRT, n (%) | |||
Yes | 19 (30.6) | 12 (28.6) | 0.82 |
No | 43 (69.4) | 30 (71.4) | |
